Fate Therapeutics, Inc.(FATE)

Description: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

---

Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Stem Cell Hematologic Malignancies Induced Stem Cells Cord Blood Adult Stem Cell Hematopoietic Stem Cell Orphan Disease Umbilical Cord Blood Cells Lysosomal Storage Disorder Lysosomal Storage Disorders Muscular Dystrophies

---

Home Page: www.fatetherapeutics.com

FATE Technical Analysis

12278 Scripps Summit Drive
San Diego, CA 92131
United States
Phone: 858 875 1800

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)